LadRx Corp Files Definitive Proxy Statement

TL;DR

LadRx Corp filed its proxy statement - shareholders vote soon.

AI Summary

LadRx Corp filed its definitive proxy statement on August 20, 2024, detailing information for its annual meeting. The filing, under the SEC Act of 1934, concerns the company's governance and shareholder matters. LadRx Corp, formerly Cytrx Corp, is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing provides shareholders with crucial information regarding the company's leadership, voting matters, and financial oversight, enabling informed participation in corporate decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial performance data or significant corporate actions that would inherently increase risk.

Key Numbers

• 000-15327 — SEC File Number (Identifies the specific SEC filing for LadRx Corp.)
• 241222530 — Film Number (Internal SEC processing number for the filing.)

Key Players & Entities

• LadRx Corp (company) — Registrant
• Cytrx Corp (company) — Former company name
• 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA 90049 (address) — Business and Mailing Address
• 310-826-5648 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.001 — ven to the holders of the common stock, $0.001 par value per share (the “Common

Filing Documents

• formdef14a.htm (DEF 14A) — 390KB
• chart_001.jpg (GRAPHIC) — 157KB
• chart_002.jpg (GRAPHIC) — 186KB
• proxy_001.jpg (GRAPHIC) — 397KB
• proxy_002.jpg (GRAPHIC) — 465KB
• 0001493152-24-033214.txt ( ) — 2052KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 17 COMPENSATION OF DIRECTORS 22 PAY VERSUS PERFORMANCE 23 PROPOSAL 2 — RATIFICATION OF THE APPOINTMENT WEINBERG & COMPANY AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE 2024 FISCAL YEAR 26 PROPOSAL 3 — ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS 27 STOCKHOLDER PROPOSALS FOR THE 2025 ANNUAL MEETING OF STOCKHOLDERS 28 OTHER MATTERS 29 WHERE YOU CAN FIND MORE INFORMATION 30 LadRx Corporation 11726 San Vicente Boulevard, Suite 650 Los Angeles, California 90049 To be held on October 4, 2024 PROXY GENERAL INFORMATION This proxy statement (the “Proxy Statement”) is furnished to holders of the common stock, $0.001 par value per share (the “Common Stock”) of LadRx Corporation, a Delaware corporation (“we,” “us,” “our,” “LadRx” or the “Company”), in connection with the solicitation of proxies by our board of directors (the “Board of Directors” or “Board”) on behalf of the Company for use at our Annual Meeting of Stockholders to be held at 11726 San Vicente Boulevard, Suite 650, Los Angeles, CA 90049, local time, on Friday, October 4, 2024 and at any postponement or adjournment thereof. This Proxy Statement and the accompanying proxy materials are first being furnished to our stockholders on or about August 20, 2024. Our Board of Directors is asking you to vote your shares as described below. If you attend the Annual Meeting in person, you may vote at the Annual Meeting even if you have previously submitted a proxy. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder. In accordance with the rules of the Securities and Exchange Commission (the “SEC”), we are furnishing our pr

View Full Filing

View this DEF 14A filing on SEC EDGAR